[{"id":"e9f712c9-43ca-4d3b-9a6c-4c80e514d787","acronym":"NCI-2018-01503","url":"https://clinicaltrials.gov/study/NCT03587311","created_at":"2021-01-29T07:17:35.675Z","updated_at":"2024-07-02T16:35:02.670Z","phase":"Phase 2","brief_title":"Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","source_id_and_acronym":"NCT03587311 - NCI-2018-01503","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Krabeva (bevacizumab biosimilar) • anetumab ravtansine (BAY 94-9343) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 10/12/2018","start_date":" 10/12/2018","primary_txt":" Primary completion: 10/21/2024","primary_completion_date":" 10/21/2024","study_txt":" Completion: 10/21/2024","study_completion_date":" 10/21/2024","last_update_posted":"2024-05-17"},{"id":"09261b2f-42ac-4b72-856f-4daf46603021","acronym":"NCI10208","url":"https://clinicaltrials.gov/study/NCT03816358","created_at":"2021-01-18T18:51:22.211Z","updated_at":"2024-07-02T16:35:03.288Z","phase":"Phase 1","brief_title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","source_id_and_acronym":"NCT03816358 - NCI10208","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • gemcitabine • anetumab ravtansine (BAY 94-9343) • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 12/09/2019","start_date":" 12/09/2019","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2025","study_completion_date":" 01/31/2025","last_update_posted":"2024-05-16"},{"id":"549a7364-24ed-4cb0-a1a5-48fe62ef459e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05804526","created_at":"2023-04-07T13:03:06.963Z","updated_at":"2024-07-02T16:35:07.029Z","phase":"Phase 1/2","brief_title":"A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours","source_id_and_acronym":"NCT05804526","lead_sponsor":"RemeGen Co., Ltd.","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tyvyt (sintilimab) • Loqtorzi (toripalimab-tpzi) • misitatug blivedotin (RC88)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-30"},{"id":"237b354a-5aa6-4026-9efe-63dba3502553","acronym":"","url":"https://clinicaltrials.gov/study/NCT05451849","created_at":"2022-07-11T11:54:54.962Z","updated_at":"2024-07-02T16:35:16.022Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT05451849","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • TC-510"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 06/21/2022","start_date":" 06/21/2022","primary_txt":" Primary completion: 10/30/2028","primary_completion_date":" 10/30/2028","study_txt":" Completion: 10/30/2028","study_completion_date":" 10/30/2028","last_update_posted":"2024-03-06"},{"id":"f8516452-54df-4277-8f56-8aa72d1fb00e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03907852","created_at":"2021-01-18T19:14:14.258Z","updated_at":"2024-07-02T16:35:16.164Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","source_id_and_acronym":"NCT03907852","lead_sponsor":"TCR2 Therapeutics","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • cyclophosphamide • gavocabtagene autoleucel (TC-210) • fludarabine IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/15/2019","start_date":" 04/15/2019","primary_txt":" Primary completion: 11/02/2028","primary_completion_date":" 11/02/2028","study_txt":" Completion: 11/02/2028","study_completion_date":" 11/02/2028","last_update_posted":"2024-03-06"},{"id":"77e12794-7dd2-4ce2-bacc-b40dca21f7bd","acronym":"","url":"https://clinicaltrials.gov/study/NCT05375825","created_at":"2022-05-17T12:54:06.483Z","updated_at":"2024-07-02T16:35:21.326Z","phase":"Phase 1","brief_title":"Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin","source_id_and_acronym":"NCT05375825","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LMB-100"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 42","initiation":"Initiation: 02/06/2024","start_date":" 02/06/2024","primary_txt":" Primary completion: 12/18/2024","primary_completion_date":" 12/18/2024","study_txt":" Completion: 12/18/2024","study_completion_date":" 12/18/2024","last_update_posted":"2024-02-01"},{"id":"99889667-7df9-4ba0-9746-9b7586ccaa67","acronym":"","url":"https://clinicaltrials.gov/study/NCT05779917","created_at":"2023-03-22T14:03:05.395Z","updated_at":"2024-07-02T16:35:29.095Z","phase":"Phase 1","brief_title":"Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT05779917","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mesothelin/GPC3/GUCY2C-CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 03/10/2023","start_date":" 03/10/2023","primary_txt":" Primary completion: 03/10/2026","primary_completion_date":" 03/10/2026","study_txt":" Completion: 03/10/2033","study_completion_date":" 03/10/2033","last_update_posted":"2023-11-15"},{"id":"ca161a5b-e2be-463d-91d5-d7590fad91e0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01393483","created_at":"2021-01-18T05:43:20.137Z","updated_at":"2024-07-02T16:35:34.994Z","phase":"","brief_title":"Evaluate Mesothelin as a Biomarker for the Clinical Management of Esophageal Adenocarcinoma (EAC)","source_id_and_acronym":"NCT01393483","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 371","initiation":"Initiation: 03/01/2011","start_date":" 03/01/2011","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 09/01/2024","study_completion_date":" 09/01/2024","last_update_posted":"2023-10-03"},{"id":"5deea24a-3e42-4778-ab8c-7a751c529263","acronym":"","url":"https://clinicaltrials.gov/study/NCT04727554","created_at":"2021-01-29T07:21:48.844Z","updated_at":"2024-07-02T16:35:36.003Z","phase":"Phase 1","brief_title":"Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT04727554","lead_sponsor":"Amgen","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e inezetamab (AMG994) • zeluvalimab (AMG 404)"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/29/2021","start_date":" 04/29/2021","primary_txt":" Primary completion: 06/05/2023","primary_completion_date":" 06/05/2023","study_txt":" Completion: 06/05/2023","study_completion_date":" 06/05/2023","last_update_posted":"2023-09-22"},{"id":"dea692c6-2a2d-42ac-a72b-d9197b7cfc2f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05686720","created_at":"2023-01-17T14:59:19.477Z","updated_at":"2024-07-02T16:35:57.570Z","phase":"Phase 1","brief_title":"Single-arm, Open-label Clinical Study of SZ011 in the Treatment of Advanced Triple Negative Breast Cancer","source_id_and_acronym":"NCT05686720","lead_sponsor":"First Affiliated Hospital of Shantou University Medical College","biomarkers":" HER-2 • ER • PGR • MSLN","pipe":" | ","alterations":" HER-2 negative • ER negative • MSLN positive • PGR negative","tags":["HER-2 • ER • PGR • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • ER negative • MSLN positive • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SZ011"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 02/01/2024","primary_completion_date":" 02/01/2024","study_txt":" Completion: 06/01/2024","study_completion_date":" 06/01/2024","last_update_posted":"2023-01-16"},{"id":"5680e6c0-6a5a-4e90-aaac-028889578a1e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05141253","created_at":"2021-12-02T18:54:25.304Z","updated_at":"2024-07-02T16:36:11.366Z","phase":"Phase 1","brief_title":"Safety and Efficacy of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05141253","lead_sponsor":"Tongji Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/12/2022","start_date":" 01/12/2022","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2036","study_completion_date":" 11/01/2036","last_update_posted":"2022-04-27"},{"id":"4465b15f-e650-40db-95ec-d8d83a386576","acronym":"","url":"https://clinicaltrials.gov/study/NCT05344976","created_at":"2022-04-25T21:58:14.342Z","updated_at":"2024-07-02T16:36:11.525Z","phase":"Phase 1","brief_title":"MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05344976","lead_sponsor":"Peking University","biomarkers":" EGFR • ALK • MET • ROS1 • MSLN","pipe":" | ","alterations":" ALK positive • EGFR positive • EGFR negative • MSLN positive","tags":["EGFR • ALK • MET • ROS1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • EGFR positive • EGFR negative • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YTS105"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2022","start_date":" 04/14/2022","primary_txt":" Primary completion: 10/14/2024","primary_completion_date":" 10/14/2024","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2022-04-25"},{"id":"2d23aab4-1f16-4ace-937a-0b431ccf7367","acronym":"","url":"https://clinicaltrials.gov/study/NCT05166070","created_at":"2021-12-21T15:53:43.976Z","updated_at":"2024-07-02T16:36:19.299Z","phase":"Phase 1","brief_title":"An Exploratory Clinical Study of RD133 in Subjects With Relapsed or Refractory MSLN-Positive Solid Tumors","source_id_and_acronym":"NCT05166070","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RD133"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 01/01/2022","start_date":" 01/01/2022","primary_txt":" Primary completion: 01/01/2024","primary_completion_date":" 01/01/2024","study_txt":" Completion: 01/01/2037","study_completion_date":" 01/01/2037","last_update_posted":"2021-12-21"},{"id":"c57218fe-9186-4e3a-b510-e014a45f68cf","acronym":"Amaretto","url":"https://clinicaltrials.gov/study/NCT04981691","created_at":"2021-07-29T14:53:07.374Z","updated_at":"2024-07-02T16:36:24.273Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR-T Cells With Advanced Refractory Solid Tumors","source_id_and_acronym":"NCT04981691 - Amaretto","lead_sponsor":"Ruijin Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • UCLM802"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 01/09/2022","primary_completion_date":" 01/09/2022","study_txt":" Completion: 07/09/2022","study_completion_date":" 07/09/2022","last_update_posted":"2021-09-17"},{"id":"fea520a7-4eba-4fdf-b9d4-98fbf0b1455e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03814447","created_at":"2021-01-18T18:50:52.538Z","updated_at":"2024-07-02T16:36:26.671Z","phase":"Phase 1","brief_title":"The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer","source_id_and_acronym":"NCT03814447","lead_sponsor":"Shanghai 6th People's Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 08/16/2019","start_date":" 08/16/2019","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2021-08-10"},{"id":"046bd970-a819-491c-b309-6d96f8ea30b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03941626","created_at":"2021-01-19T18:01:10.172Z","updated_at":"2024-07-02T16:36:35.027Z","phase":"Phase 1/2","brief_title":"Autologous CAR-T/TCR-T Cell Immunotherapy for Solid Malignancies","source_id_and_acronym":"NCT03941626","lead_sponsor":"Shenzhen BinDeBio Ltd.","biomarkers":" HLA-A • MSLN • CTAG1B","pipe":" | ","alterations":" HLA-A*02:01 • MSLN positive • HLA-A positive","tags":["HLA-A • MSLN • CTAG1B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02:01 • MSLN positive • HLA-A positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • multi-target gene-modified CAR-T/TCR-T cell immunotherapy"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 05/01/2021","primary_completion_date":" 05/01/2021","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-04"},{"id":"299058dd-8801-4728-862b-b08c1fdf3994","acronym":"","url":"https://clinicaltrials.gov/study/NCT04627740","created_at":"2021-01-29T07:21:35.908Z","updated_at":"2024-07-02T16:36:38.710Z","phase":"Phase 1/2","brief_title":"Anti-ALPP CAR-T Cells Immunotherapy for Ovarian and Endometrial Cancer","source_id_and_acronym":"NCT04627740","lead_sponsor":"Xinqiao Hospital of Chongqing","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • TC-A101"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 12/31/2022","primary_completion_date":" 12/31/2022","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2020-11-13"},{"id":"864e20df-a59c-41cd-b490-615021eb2ec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03545815","created_at":"2021-01-18T17:27:27.742Z","updated_at":"2024-07-02T16:36:42.187Z","phase":"Phase 1","brief_title":"Study of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.","source_id_and_acronym":"NCT03545815","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GC008t • MPTK-CAR-T cells • MSLN CAR-T"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 03/19/2018","start_date":" 03/19/2018","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 12/30/2020","study_completion_date":" 12/30/2020","last_update_posted":"2020-08-10"},{"id":"371b0717-a8ed-4558-aa51-7905f2ad1929","acronym":"","url":"https://clinicaltrials.gov/study/NCT03916679","created_at":"2021-01-29T07:19:10.073Z","updated_at":"2024-07-02T16:37:00.582Z","phase":"Phase 1/2","brief_title":"MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03916679","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/20/2019","start_date":" 04/20/2019","primary_txt":" Primary completion: 04/20/2022","primary_completion_date":" 04/20/2022","study_txt":" Completion: 04/20/2023","study_completion_date":" 04/20/2023","last_update_posted":"2019-04-16"},{"id":"d807f944-6769-4d81-ab96-ee3a7e16288c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03799913","created_at":"2021-01-29T07:18:35.470Z","updated_at":"2024-07-02T16:37:00.741Z","phase":"Phase 1","brief_title":"MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer","source_id_and_acronym":"NCT03799913","lead_sponsor":"Zhejiang University","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • anti- MESO CAR-T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 04/10/2019","start_date":" 04/10/2019","primary_txt":" Primary completion: 10/01/2021","primary_completion_date":" 10/01/2021","study_txt":" Completion: 04/01/2022","study_completion_date":" 04/01/2022","last_update_posted":"2019-04-10"},{"id":"38a358aa-4637-4d62-88fe-5f1f4ce41f8d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03692637","created_at":"2021-01-18T18:05:54.027Z","updated_at":"2024-07-02T16:37:03.340Z","phase":"Phase 1","brief_title":"Study of Anti-Mesothelin Car NK Cells in Epithelial Ovarian Cancer","source_id_and_acronym":"NCT03692637","lead_sponsor":"Allife Medical Science and Technology Co., Ltd.","biomarkers":" PD-L1 • PD-1 • MSLN","pipe":" | ","alterations":" MSLN expression • MSLN positive","tags":["PD-L1 • PD-1 • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN CAR-T • anti-Mesothelin CAR NK Cells"],"overall_status":"Unknown status","enrollment":" Enrollment 30","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 11/01/2020","primary_completion_date":" 11/01/2020","study_txt":" Completion: 11/01/2021","study_completion_date":" 11/01/2021","last_update_posted":"2019-01-31"},{"id":"6ec895e3-f79e-43a0-b8a4-dabd649c51b0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03747965","created_at":"2021-01-18T18:22:50.032Z","updated_at":"2024-07-02T16:37:05.167Z","phase":"Phase 1","brief_title":"Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors","source_id_and_acronym":"NCT03747965","lead_sponsor":"Chinese PLA General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • cyclophosphamide • GC008t"],"overall_status":"Unknown status","enrollment":" Enrollment 10","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 11/01/2019","primary_completion_date":" 11/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2018-11-20"},{"id":"f19e2ec4-0a2a-400d-a370-b85f74fad188","acronym":"","url":"https://clinicaltrials.gov/study/NCT03030001","created_at":"2021-01-18T14:54:50.449Z","updated_at":"2024-07-02T16:37:26.304Z","phase":"Phase 1/2","brief_title":"PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies","source_id_and_acronym":"NCT03030001","lead_sponsor":"Ningbo Cancer Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 02/15/2017","start_date":" 02/15/2017","primary_txt":" Primary completion: 12/01/2018","primary_completion_date":" 12/01/2018","study_txt":" Completion: 02/01/2019","study_completion_date":" 02/01/2019","last_update_posted":"2017-01-24"},{"id":"40516fe7-06f1-4482-9d62-ee5ed2208d4a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02930993","created_at":"2021-01-18T14:23:37.310Z","updated_at":"2024-07-02T16:37:28.541Z","phase":"Phase 1","brief_title":"Anti-mesothelin CAR T Cells for Patients With Recurrent or Metastatic Malignant Tumors","source_id_and_acronym":"NCT02930993","lead_sponsor":"China Meitan General Hospital","biomarkers":" MSLN","pipe":" | ","alterations":" MSLN positive","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • MSLN CAR-T • anti-mesothelin CAR T cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 08/01/2016","start_date":" 08/01/2016","primary_txt":" Primary completion: 08/01/2018","primary_completion_date":" 08/01/2018","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2016-10-12"}]